Clinical Trials Details

EA1181 CompassHER2-pCR (Breast)

Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer

Objective

Key eligibility: 

• Stage II or IIIA HER2+
  • cNO if T size > 2 cm
  • cN1-2 if T size is 1-3 cm
  • ER+ & ER- are eligible
• H2+/ER+ T size > 2 cm <3 cm & cNO arm is closed

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms